Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications
Dual Lineage Tracing Identifies Cellular Mechanisms Underlying Radiation-Associated Changes in Atherosclerotic Lesion Composition.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: August 06, 2026
Dual Lineage Tracing Identifies Cellular Mechanisms Underlying Radiation-Associated Changes in Atherosclerotic Lesion Composition.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Journal: Dermatology and therapy
Published: March 06, 2025
Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.
Journal: Rheumatology and therapy
Published: February 24, 2025
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.
Journal: The Journal of dermatology
Published: February 08, 2025
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.
Journal: Lupus science & medicine
Published: January 29, 2025
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study.
Journal: Lupus science & medicine
Published: December 19, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
Journal: JAMA dermatology
Published: November 27, 2024
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 23, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study.
Journal: The Journal of dermatology
Published: July 30, 2024
Contemporary Long-term Survival Outcomes and Prognostic Factors in Adult grade 4 Astrocytoma: An Institutional Analysis.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: July 07, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
Journal: The Journal of dermatological treatment
Published: June 30, 2024
Last Updated: 09/26/2026